Search results
Results from the WOW.Com Content Network
Cetuximab, sold under the brand name Erbitux, is an epidermal growth factor receptor (EGFR) inhibitor medication used for the treatment of metastatic colorectal cancer and head and neck cancer. [2] Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion .
The other agent that is widely used is Cetuximab, a monoclonal antibody directed at the epidermal growth factor receptor (EGFR). A 10% survival advantage at three years was noted when cetuximab was given concurrently with radiation (bioradiation). [169] Cetuximab trials were completed before knowledge of HPV status. [170]
In July 2009, the FDA updated the labels of two anti-EGFR monoclonal antibody drugs (panitumumab and cetuximab) indicated for the treatment of metastatic colorectal cancer to include information about KRAS mutations. [14] This was the result of a study, which demonstrated lack of benefit with Panitumumab in patients who carried NRAS mutations. [6]
It directs cell fate decision relating to cell growth, survival and, differentiation. Development of matuzumab and other antibodies to the EGFR (for example cetuximab) as cancer therapeutics was motivated by observations that EGFR expression and/or signaling is frequently upregulated in cancer cells.
Ensure women are aware of their cancer profile early. "All women should know their cancer risk profile by the age of 30," Litvack says. "We all need to be in control of our own health, having the ...
A report from the U.S. surgeon general suggested that labels on alcoholic drinks should warn about cancer risk. Doctors expressed their agreement. For people wondering about the long-term damage ...
Alcohol and cancer risk is an issue that’s been developing “for a long time” in other countries, said Hay. “This is a really important and positive movement for the U.S. to acknowledge ...
Another avenue for novel anti-cancer therapies is re-engineering some of the currently used conventional antibodies like trastuzumab (targeting HER2/neu), cetuximab and panitumumab (both targeting the EGF receptor), using the BiTE approach. [27] As of 2009, BiTEs against CD66e and EphA2 are being developed as well. [28]